DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for pyridoxine-dependent epilepsy — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePyridoxine-dependent epilepsy maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pyridoxine-dependent epilepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
aldehyde dehydrogenase 7 family member A1 (ALDH7A1) — ALDH7A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet naddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6O4C · 1.7 Å · ligand NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD). Experimental structure, not a prediction.
What the evidence adds up to
In 1985, three infants with atypical pyridoxine-dependent seizures were reported, each showing either late onset of convulsions or seizure-free intervals of several months without pyridoxine. The authors, combining their cases with nine previously reported ones, recommended a trial of pyridoxine for all seizure disorders beginning before 18 months of age, regardless of seizure type. No response rates or survival figures were given.
A 2016 Indian study of children with refractory epilepsy found that 3.5% of cases were due to pyridoxine-dependent convulsions. Among 13.3% of paediatric inpatients who met International League Against Epilepsy criteria for refractory epilepsy, 34.4% had neurometabolic diseases. The pyridoxine-dependent subgroup showed what the authors called an excellent response to dietary manipulation, disease-modifying treatment, and small-dose anticonvulsants. They reported that seizure control and neurodevelopmental improvement became evident within two weeks, and at one-year follow-up most children achieved independence for daily activities with minimal cost, almost no side effects, and no need for palliative surgery. The sample size of this subgroup was not stated, and no control group was used.
A 2010 European study characterised the genetic basis of pyridoxine-dependent epilepsy by measuring urinary alpha-aminoadipic semialdehyde and analysing the ALDH7A1 gene encoding antiquitin. That abstract provides no treatment outcomes, only a description of the diagnostic approach.
What is still missing is a randomised controlled trial of pyridoxine versus placebo or standard anticonvulsants in infants with unexplained seizures, with blinded outcome assessment and long-term neurodevelopmental follow-up. The 2016 study lacked a control arm and did not specify how many children received pyridoxine alone versus other treatments. No trial has stratified patients by ALDH7A1 mutation status to test whether genetic confirmation predicts response. Funding for such a trial, particularly in low-resource settings where refractory epilepsy is common, remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Neurology · 1985 · 126 citations
Atypical presentations of pyridoxine‐dependent seizures: A treatable cause of intractable epilepsy in infants
AbstractWe report on 3 patients with atypical pyridoxine-dependent seizures. Each had either late onset of convulsions (2 cases) or seizure-free intervals of up to several months' duration in the absence of pyridoxine supplementation. The findings, taken together with those in 9 previously reported cases, indicate that a trial of pyridoxine should be performed in all seizure disorders with onset before 18 months of age, regardless of type.
Journal of Pediatric Neurosciences · 2016 · 3 citations
Pyridoxine-dependent convulsions among children with refractory seizures: A 3-year follow-up study
AbstractINTRODUCTION: Epilepsy accounts for 1% of the global disease burden and about 8-10 million epilepsy patients live in India. About 30-40% of these patients become drug-resistant and land up with palliative or disease-modifying surgeries. This is a situation causing great concern in view of the psychosocial and economic burden on the patient and the family apart from severe cognitive and motor consequences, especially in children. Therefore, it is mandatory to have an insight into the wide spectrum of causes with reference to refractoriness to antiepileptic medications in children with epilepsy. PATIENTS AND METHODS: Children admitted under our team with refractory epilepsy as per the International League Against Epilepsy (ILAE) criteria in the last 3 years were included in the study. RESULTS: Refractory epilepsy constituted 13.3% of inpatients in the pediatric group. Males dominated with 68.9% of these patients. Nearly 34.4% of these patients were found to suffer from various neurometabolic diseases. Almost 3.5% were due to pyridoxine-dependent convulsions. This group of patients showed an excellent response to dietary manipulation, disease-modifying treatment for the metabolic disorder, and supportive small-dose anticonvulsants. During follow-up, they showed very good response with reference to global development and seizure control. CONCLUSION: Pyridoxine-dependent convulsions are relatively rare forming about 3.5% of refractory epilepsies in this series. With initiation of appropriate therapy, results with reference to seizure control as well as neurodevelopment became evident within 2 weeks, and at 1-year follow-up, complete independence for majority of the needed activities is achieved with minimum cost, almost zero side effects, and absolute elimination of the need for palliative surgery.
Galter Health Sciences Library, Northwestern University · 2010 · 0 citations · open access
ALDH7A1 Deficiency and Pyridoxine-Dependent Epilepsy
AbstractResearchers at University College and Great Ormond Street Hospital for Children, London, and other centers in the UK and Europe investigated the genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (PDE) by measurement of urinary alpha-aminoadipic semialdehyde (a-AASA) concentration and mutational analysis of the ALDH7A1 gene that encodes antiquitin.
ALDH7A1 Deficiency and Pyridoxine-Dependent Epilepsy
AbstractResearchers at University College and Great Ormond Street Hospital for Children, London, and other centers in the UK and Europe investigated the genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (PDE) by measurement of urinary alpha-aminoadipic semialdehyde (a-AASA) concentration and mutational analysis of the ALDH7A1 gene that encodes antiquitin.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
